How to Choose a Medical Device Regulatory Consultant in Korea — 7 Criteria to Check

Key takeaway — You do not need advertising copy to judge a medical device regulatory consulting firm: check three things — how the quote is structured, how the track record is evidenced, and how staffing is organized — and most of the judgment settles itself. Instead of recommending specific firms, this guide sets out seven criteria and the exact questions you can put on the table at any consultation.

1. Is the quote split into statutory fees, third-party costs, and the consulting fee?
2. Is the track record proven with issued documents?
3. Does the same person stay on your file through issuance?
4. Has the firm handled your product category and class?
5. Is deficiency response within the contract scope?
6. Are testing and KGMP connected in a single flow?
7. Does the firm bring up post-approval obligations first?

Why criteria to check, not a list to trust

Regulatory consulting is a service whose quality is hard to verify from the outside until the deliverable arrives. Website copy, cumulative case counts, search rankings — all of it is what the firm says about itself, and none of it cross-checks easily.

Fortunately, three kinds of things in this industry are verifiable from the outside: published fixed values (statutory fees), officially issued documents (notification, certification, and approval certificates; KGMP conformity certificates), and defined procedures (the rules governing review and deficiency response). Each of the seven criteria below hangs a question on one of these verifiable points, so that the way a firm actually works surfaces at the consultation stage.

Criterion 1 — Is the quote split three ways?

The cost of medical device registration in Korea mixes money of entirely different kinds.

• Government statutory fees — fixed amounts published in Annex 10 of the Enforcement Rule of the Medical Devices Act. On an electronic filing basis: KRW 85,000 for a Class 1 notification, KRW 130,000 for a Class 2 certification, KRW 719,000 for a Class 3·4 approval including technical file review — KRW 1,495,000 when clinical data review is included. The amount is the same no matter who files.
• Review body and testing laboratory costs — the Class 2 technical file review fee and the KGMP audit fee follow the published rates of the review bodies (KTL, KTR, and others), and testing charges are paid directly to the laboratory, per product.
• The consulting fee — the firm’s own share. It varies with product difficulty, number of models, and the state of your documentation, so before it is finalized, it is natural to see it quoted as a “from” price (a floor). If so, ask in the same breath what makes it go up, and by how much.

If these three are rolled into an undifferentiated “all-in total of ₩X million,” you cannot tell where the money owed to the authorities ends and the firm’s share begins — comparison across firms simply does not hold. And the reaction when you ask for an itemized quote is itself information. The full statutory fee table and per-class procedures and timelines are published on our regulatory consulting page.

Question to ask — “Will you itemize government statutory fees and review body costs separately from your own fee on the quote?”

Criterion 2 — Is the track record proven with issued documents?

Claims like “X hundred cumulative cases” come with no means of verification. By contrast, every outcome in this field is issued as a document — notification, certification, and approval certificates; KGMP conformity certificates. Issued documents are direct evidence of track record, and they can be shown perfectly well with client details masked.

When you look at the documents, check two things: whether there are recent issuances (or only the same old wins on repeat display), and whether the track record overlaps with your product category and class. If the firm says it cannot show any, ask why; if the answer is another round of case-count claims with no clear reason, that is one more data point for your decision.

Question to ask — “Can you show me recently issued certificates or KGMP conformity certificates, even in masked form?”

Criterion 3 — Does the same person stay on until issuance?

A registration project runs weeks at minimum and can cross into the next year. If the person you consulted is not the person assigned after signing, and the file changes hands again mid-project, you end up explaining your product from scratch every time.

Re-explaining is not just lost time. A technical file written by someone with a shallow grasp of the product drifts out of line with the specifications and test reports, and that inconsistency comes back as a deficiency notice. Where a handover is genuinely unavoidable, the next-best thing to verify is whether the handover procedure is documented.

Question to ask — “Will the person in charge stay the same from consultation to issuance? If not, how does the handover work?”

Criterion 4 — Has the firm handled my product category and class?

Years in the business and knowledge of your product are different things. Electrical stimulation devices and software as a medical device, in-vitro diagnostics and implants — each carries different applicable standards, test items, and review issues. An answer like “we cover all medical devices” is worth less, as evidence, than a concrete account of what the review issues were in your product category and class.

No direct case in your category is not an automatic disqualifier. In that situation, the substitute indicator is whether the firm can reason through, right there in the consultation, which product standards would apply and which tests would be needed.

Question to ask — “Do you have cases in this product category and class? If so, what were the review issues?”

Criterion 5 — Is deficiency response within the contract scope?

In device review, deficiency notices are closer to routine than exception, and the response period is excluded from the statutory processing time — which is why most schedule slippage happens here. So the thing to read in the contract before the upfront price is the terms for handling deficiencies.

• How many rounds of deficiency response are included in the base consulting fee?
• What does each additional round cost?
• If a deficiency forces retesting, who bears the cost?

If these three are not in the contract, the final cost is unknowable at signing — and in that state, comparison with other firms’ quotes does not hold either.

Question to ask — “How many rounds of deficiency response are included, and how are extra rounds and retesting costs handled?”

Criterion 6 — Are testing and KGMP connected in a single flow?

For Class 2 and above, the technical file, testing, and KGMP are not separate procedures — they are one bundle passing figures back and forth. The performance values in the technical file must be substantiated by the test reports, and the quality system documents must match the specifications in the technical file.

Split these across different providers and, when an inconsistency appears between documents, there is no one to reconcile it — the first conversation becomes an argument over responsibility. This does not mean everything must go to a single firm. It means that even if you split the work, someone must be designated to manage overall consistency.

Question to ask — “Do test design and KGMP response fall within your scope? If not, who manages consistency across the documents?”

Criterion 7 — Does the firm talk about what comes after approval?

Issuance is not the end — it is the start of maintenance obligations. UDI registration, monthly supply reporting, change approval or change review when specifications or labeling change, renewal when the cycle comes due, adverse event reporting — if the contract ends at issuance, all of these land on your company in one piece.

A firm that talks only up to issuance and a firm that tells you first which obligations begin, and when, are looking at the project on different horizons. Even if you have no plan to outsource post-market work, the specificity of the answer to this question is a good gauge of the firm’s practical depth.

Question to ask — “After issuance, how are UDI registration, supply reporting, and change management handled?”

The comparison checklist — fill one in at every consultation

Write down each firm’s answers as given. Yes/no plus a one-line note is enough for the comparison to hold.

#	Criterion	Question to ask	Firm A	Firm B	Firm C
1	Three-way quote split	Are statutory fees, third-party costs, and your fee itemized separately?
2	Issued-document track record	Can you show recent certificates (even masked)?
3	Staffing continuity	Same person from consultation to issuance?
4	Product-category experience	Any cases in this category and class?
5	Deficiency terms	How many rounds included; cost of extras and retests?
6	Testing–KGMP linkage	Is someone designated to manage consistency?
7	Post-market care	Do you brief on post-issuance obligations up front?

---

These seven criteria are not designed to point at any particular firm — they exist so that every firm you meet can be measured with the same yardstick. CLARE Partners welcomes being tested with the same questions: how we separate the consulting fee from statutory fees is published on our regulatory consulting page, and our issued-document track record on the results page. Whichever firm you end up working with, send us your product information for a free pre-review before you sign — we reply within one business day with a first read on class, procedure, and required scope.